A severe-airway and pulmonary-vascular drug curriculum: use bronchodilators, corticosteroids, magnesium, epinephrine and inhaled pulmonary vasodilators based on the actual respiratory mechanism rather than escalating every drug for every wheezy or hypoxemic patient.
Use SABA + ipratropium + systemic corticosteroid correctly in severe asthma/COPD exacerbation.
Recognize beta-agonist hypokalemia and hyperlactatemia during continuous treatment.
Use magnesium selectively in severe asthma not responding to initial therapy.
Give IM epinephrine immediately for anaphylaxis rather than substituting inhaled bronchodilators.
Use inhaled nitric oxide/epoprostenol as short-term pulmonary vascular rescue—not routine mortality therapy for ARDS.
Compare hydrocortisone, methylprednisolone and dexamethasone by ICU indication.
The table below is a selection framework. Open the individual monograph for exact dosing, preparation, renal/CRRT/IHD adjustment, interactions and evidence traceability.
ICU role: Primary short-acting beta-2 rescue bronchodilator.
Monitor: Airflow/air entry, HR/rhythm, K and lactate during prolonged high-dose use.
ICU role: Short-acting antimuscarinic bronchodilator.
Monitor: Clinical airflow response and anticholinergic adverse effects.
ICU role: Systemic glucocorticoid for severe obstructive/inflammatory pulmonary disease when IV therapy is needed.
Monitor: Glucose, infection, neuromuscular/mental status.
ICU role: Long-acting glucocorticoid used in selected pulmonary/inflammatory indications.
Monitor: Glucose, infection, mental status.
ICU role: Adjunct bronchodilator for selected severe asthma refractory to initial inhaled therapy.
Monitor: BP, reflexes/respiration with substantial exposure, renal function.
ICU role: First-line anaphylaxis drug and selected peri-arrest airway rescue—not routine asthma drug without anaphylaxis.
Monitor: Airway, BP/HR, perfusion and recurrence.
ICU role: Dissociative anesthetic with bronchodilatory properties useful for selected intubation/sedation scenarios.
Monitor: BP/HR, sedation, secretions and ventilation.
ICU role: Selective inhaled pulmonary vasodilator for acute RV/pulmonary hypertensive rescue and selected refractory hypoxemia.
Monitor: Oxygenation, RV response, methemoglobin, weaning/rebound.
ICU role: Inhaled prostacyclin pulmonary vasodilator for RV failure/PH and selected oxygenation rescue.
Monitor: Oxygenation, systemic BP, RV response, delivery system.
| Agent | ICU role | Why I choose it | Why I hesitate | What I monitor |
|---|---|---|---|---|
| Albuterol (Salbutamol) Short-Acting Selective Beta-2 Adrenergic Agonist (SABA) | Primary short-acting beta-2 rescue bronchodilator. | ✓ Repeated/continuous inhaled therapy for severe asthma and acute COPD bronchospasm. | ✕ Tachycardia, hypokalemia and beta-agonist lactate can complicate high-dose therapy. | Airflow/air entry, HR/rhythm, K and lactate during prolonged high-dose use. |
| Ipratropium Bromide Short-Acting Inhaled Muscarinic Antagonist (SAMA) | Short-acting antimuscarinic bronchodilator. | ✓ Add to SABA in moderate/severe asthma and use as a core bronchodilator in COPD exacerbation. | ✕ Not a replacement for SABA in severe asthma; avoid aerosol eye exposure in narrow-angle glaucoma. | Clinical airflow response and anticholinergic adverse effects. |
| Methylprednisolone Intermediate-Acting Synthetic Glucocorticoid with Minimal Mineralocorticoid Activity | Systemic glucocorticoid for severe obstructive/inflammatory pulmonary disease when IV therapy is needed. | ✓ Useful when severe asthma/COPD requires systemic steroid and oral therapy is not feasible. | ✕ More drug is not necessarily better; monitor hyperglycemia, delirium, infection and myopathy. | Glucose, infection, neuromuscular/mental status. |
| Dexamethasone Long-Acting Synthetic Fluorinated Glucocorticoid (High Anti-Inflammatory Potency) with Negligible Mineralocorticoid Activity | Long-acting glucocorticoid used in selected pulmonary/inflammatory indications. | ✓ Useful when a long-acting potent steroid fits the disease-specific protocol. | ✕ Does not provide bronchodilation and is not a substitute for rapid airway rescue. | Glucose, infection, mental status. |
| Magnesium Sulfate Electrolyte / Multi-Mechanism Membrane & Neuromuscular Modulator | Adjunct bronchodilator for selected severe asthma refractory to initial inhaled therapy. | ✓ Consider IV magnesium in severe exacerbation not responding adequately to initial treatment. | ✕ Not a routine substitute for SABA/ipratropium/steroid; renal failure increases toxicity risk. | BP, reflexes/respiration with substantial exposure, renal function. |
| Epinephrine Potent Alpha-1, Beta-1, and Beta-2 Adrenergic Agonist | First-line anaphylaxis drug and selected peri-arrest airway rescue—not routine asthma drug without anaphylaxis. | ✓ IM epinephrine immediately for anaphylaxis with airway/bronchospasm or shock. | ✕ Do not delay IM epinephrine while trying antihistamines or nebulizers; routine use for non-anaphylactic asthma is not recommended. | Airway, BP/HR, perfusion and recurrence. |
| Ketamine Dissociative NMDA Receptor Antagonist | Dissociative anesthetic with bronchodilatory properties useful for selected intubation/sedation scenarios. | ✓ Can be advantageous for induction in severe bronchospasm when its hemodynamic profile is acceptable. | ✕ Do not rely on ketamine as definitive asthma therapy; catecholamine-depleted shock can still become hypotensive. | BP/HR, sedation, secretions and ventilation. |
| Inhaled Nitric Oxide Selective inhaled pulmonary vasodilator | Selective inhaled pulmonary vasodilator for acute RV/pulmonary hypertensive rescue and selected refractory hypoxemia. | ✓ Short-term rescue when reducing PVR without systemic hypotension is valuable. | ✕ No established routine mortality benefit in ARDS; rebound PH and methemoglobinemia can occur. | Oxygenation, RV response, methemoglobin, weaning/rebound. |
| Epoprostenol Prostacyclin analogue | Inhaled prostacyclin pulmonary vasodilator for RV failure/PH and selected oxygenation rescue. | ✓ Useful alternative to iNO where rapid selective pulmonary vasodilation is desired. | ✕ Transient rescue physiology is not definitive therapy; delivery interruption can abruptly remove effect. | Oxygenation, systemic BP, RV response, delivery system. |
Why: Severe asthma requires multi-mechanism treatment plus recognition of impending ventilatory failure.
Why: Epinephrine treats the airway, vascular leak and shock mechanisms of anaphylaxis.
Why: Inhaled pulmonary vasodilators can transiently improve V/Q and RV afterload but are rescue tools.
Why: Treatment toxicity can mimic unresolved respiratory distress.
Recognition becomes selection, then organ-failure adjustment, competing physiology and senior-level prioritization.
Severe wheeze, PEF markedly reduced, SpO2 91% after one albuterol treatment.
Repeat SABA, add ipratropium and systemic corticosteroid, titrate oxygen and reassess response promptly.
Minutes after antibiotic: urticaria, wheeze, stridor, BP 72/40.
Give IM epinephrine immediately and repeat as needed while managing airway, oxygenation and fluids; nebulized bronchodilator is adjunctive.
After intensive inhaled therapy and steroid, patient remains severe with quiet chest and rising PaCO2.
Consider IV magnesium if not already used, prepare controlled intubation/ventilation and treat dynamic hyperinflation; do not wait for arrest.
Continuous albuterol, improved peak pressures and air entry, but RR remains 34 and lactate rises from 2 to 7 mmol/L.
Recognize possible beta-agonist hyperlactatemia; reassess airway mechanics and reduce unnecessary beta-agonist escalation while monitoring K/lactate and the original asthma physiology.
Severe ARDS, echo shows dilated failing RV, MAP 64 on norepinephrine and hypoxemia persists despite optimized ventilation/proning.
Use a hemodynamic RV strategy: maintain systemic pressure, avoid excessive PVR, and consider a monitored inhaled iNO/epoprostenol rescue trial while evaluating definitive options such as ECMO. Do not let pulmonary vasodilation reduce systemic coronary perfusion.
Rapid inhaled beta-2 agonist used as the primary bronchodilator for acute asthma/COPD bronchospasm; repeated or continuous ICU dosing can cause tachycardia, tremor, hypokalemia and lactate elevation.
Inhaled antimuscarinic bronchodilator used with a SABA in moderate/severe acute asthma and as a core bronchodilator in COPD exacerbations; systemic anticholinergic effects are usually limited with inhaled use.
Potent parenteral glucocorticoid with ~5× the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid action — cornerstone therapy for severe asthma and COPD exacerbations, and non-resolving fibroproliferative A…
Potent long-acting glucocorticoid with negligible mineralocorticoid activity. It is used for selected indications including adjunctive acute bacterial meningitis when given before/with initial antibiotics, symptomatic vasogenic t…
Spans four genuinely distinct ICU indications — torsades de pointes, adjunctive severe asthma therapy, eclampsia/severe preeclampsia, and simple hypomagnesemia repletion — each with its own mechanism-relevant dosing; no single do…
Potent direct alpha/beta agonist for anaphylactic shock, cardiac arrest, post-cardiac arrest shock, and refractory septic shock — powerful inotrope and bronchodilator with transient hyperlactatemia.
Dissociative NMDA antagonist providing analgesia, sedation, and bronchodilatory effects; often useful for RSI or selected ICU analgo-sedation scenarios, but not universally superior to other induction/sedation agents.
Short-acting inhaled pulmonary vasodilator. In U.S. labeling, nitric oxide is approved for term/near-term neonates with hypoxic respiratory failure and pulmonary hypertension; adult ICU use for acute RV failure/pulmonary-hyperten…
Potent pulmonary and systemic vasodilator used chronically for PAH and sometimes inhaled off-label as a temporary ICU rescue for severe RV afterload/hypoxemia.
This Masterclass teaches selection and reasoning. Exact dosing, concentration, infusion preparation, renal/hepatic/RRT adjustment and monitoring must be checked in the linked medication monograph and the institution's current formulary/protocol. Local resistance patterns and regulatory drug availability can change faster than a static teaching page.